Blog

LAS VEGAS, NV / ACCESS Newswire / June 11, 2025 / ALT5 Sigma Corporation (NASDAQ:ALTS)(FRA:5AR1), a fintech specializing in turnkey, crypto-related solutions for institutions and merchants, is pleased to announce its participation in iFX EXPO International, taking place June 11, 2025, in Limassol, Cyprus.

ALT5 Sigma will exhibit at Booth #97 and is proud to be back for a second year at this flagship event. iFX EXPO has become the premier gathering in the online trading industry, setting a high standard for excellence.

ALT5’s infrastructure powers real-time stablecoin settlement, crypto payment processing, and digital asset rails for use cases ranging from cross-border merchant payments to API-driven fintech integrations and FX and trading desks seeking digital asset exposure.

“We’re excited to participate in iFX EXPO International, a premier event that brings together the brightest minds in fintech and trading. At ALT5, we’re passionate about advancing digital asset integration, and this expo offers a fantastic opportunity to connect, collaborate, and showcase how our technology is helping shape the future of finance,” said Peter Tassiopoulos, CEO of ALT5 Sigma.

Built for Scale, Designed for Compliance

ALT5 delivers an API-first, custody-ready infrastructure that enables real-time settlement, stablecoin-based payments, and digital asset capabilities at scale. Used by fintechs, payment processors, FX, trading desks, and neobanks, ALT5’s platform supports enterprise-grade integration, while aligning with evolving regulatory frameworks.

Whether building new rails for programmable payments or navigating compliant access to digital assets, ALT5 helps bridge traditional finance with emerging digital systems-offering tools designed for institutional-grade deployment.

Meet ALT5 Sigma at iFX EXPO International 2025

The ALT5 team, and product specialists, will be on-site for live demos, partner meetings, and ecosystem conversations throughout the event.

To connect, please reach out to info@alt5sigma.com or stop by Booth # 97 on the show floor.

About ALT5 Sigma Corporation

ALT5 Sigma Corporation (NASDAQ:ALTS) (FRA:5AR1) is a fintech, providing next generation blockchain-powered technologies for tokenization, trading, clearing settlement, payment, and safe keeping of digital assets. ALT5 has been a constituent of the Russell Microcap Index since June 28, 2024.

Founded in 2018, ALT5 Sigma, Inc. (a wholly owned subsidiary of ALT5 Sigma Corporation) enables the migration to a new global financial paradigm through its suite of blockchain infrastructure technologies. ALT5 Sigma, Inc., through its subsidiaries, offers two main platforms: “ALT5 Pay” and “ALT5 Prime.” The Company has processed over $5 billion USD in cryptocurrency transactions since inception.

ALT5 Pay is an award-winning cryptocurrency payment gateway that enables registered and approved global merchants to accept and make cryptocurrency payments or to integrate the ALT5 Pay payment platform into their application or operations using the plugin with WooCommerce and or ALT5 Pay’s checkout widgets and APIs. Merchants have the option to convert to fiat currency(s) automatically or to receive their payment in digital assets.

ALT5 Prime is an electronic over-the-counter trading platform that enables registered and approved customers to buy and sell digital assets. Customers can purchase digital assets with fiat and, equally, can sell digital assets and receive fiat. ALT5 Prime is available through a browser-based access mobile phone application named “ALT5 Pro” that can be downloaded from the Apple App Store, from Google Play, through ALT5 Prime’s FIX API, as well as through Broadridge Financial Solutions’ NYFIX gateway for approved customers.

The Company is also advancing the separation of its biotech business, which will continue under “Alyea Therapeutics Corporation.” Through its biotech activities, the Company is focused on bringing to market drugs with non-addictive pain-relieving properties to treat conditions that cause chronic or severe pain. Our patented product, a novel formulation of low-dose naltrexone (JAN123), is being initially developed for the treatment of Complex Regional Pain Syndrome (CRPS), an indication that causes severe, chronic pain generally affecting the arms or legs. The FDA has granted Jan123 Orphan Drug Designation for treatment of CRPS.

Forward Looking Statements

This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the profitability and prospective growth of ALT5’s platforms and business, that may include, but are not limited to, international currency risks, third-party or customer credit risks, liability claims stemming from ALT5’s services, and technology challenges for future growth or expansion. This press release also may contain statements and links relating to risks that JAN 101 will treat PAD, that JAN 123 will treat CRPS, the timing of the commencement of clinical trials, that the FDA will permit approval through a 505(b)(2) pathway for JAN 123, that upon approval JAN 101 will immediately disrupt the PAD market, and other statements, including words such as “continue”, “expect”, “intend”, “will”, “hope”, “should”, “would”, “may”, “potential”, and other similar expressions. Such statements reflect the Company’s current view with respect to future events, are subject to risks and uncertainties, and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political, and social uncertainties, and contingencies.

Many factors could cause the Company’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements described in this press release. Such factors could include, among others, those detailed in the Company’s periodic reports filed with the Securities and Exchange Commission (the “SEC”). Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the sections entitled “Risk Factors” in the Company’s filings with the SEC underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and the Company does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by law. The Company cannot assure that such statements will prove to be accurate as actual results, and future events could differ materially from those anticipated in such statements. Individuals are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

Media/Investor Relations Contact

IR@alt5sigma.com
1-800-400-2247

SOURCE: ALT5 Sigma Corp.

View the original press release on ACCESS Newswire

Two parallel goals for Canalevia-CA1 (crofelemer delayed-release tablets): To obtain full approval of the drug for treatment of chemotherapy-induced diarrhea (CID) and to expand the indication of crofelemer from CID to treatment of general, non-infectious diarrhea in dogs

Jaguar in discussions with potential partners to license and fund development and commercialization of crofelemer for the treatment of general, non-infectious diarrhea in dogs in the U.S. and/or globally

Diarrhea is one of the most common reasons for veterinary visits for dogs and the second most common reason for visits to the veterinary emergency room, yet there are currently no FDA-approved drugs to treat general diarrhea in dogs

SAN FRANCISCO, CA / ACCESS Newswire / June 11, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar), under its Jaguar Animal Health tradename for the veterinary market, today announced that the first study site has been established for Jaguar’s field study of Canalevia-CA1, Jaguar’s U.S. Food and Drug Administration (FDA) conditionally approved prescription drug for the treatment of chemotherapy-induced diarrhea (CID) in dogs.

Jaguar has two parallel goals for Canalevia-CA1 (crofelemer delayed-release tablets): To obtain full approval of the drug for treatment of chemotherapy-induced diarrhea (CID) in dogs and to expand the indication of crofelemer from CID in dogs to treatment of general, non-infectious diarrhea in dogs. The company is in discussions with potential partners to fund development and commercialization of crofelemer for the treatment of general, non-infectious diarrhea in dogs in the U.S. and/or globally.

“We’ve been pleased with the marketplace reception of crofelemer for treatment of CID in dogs, and believe there is clearly an unmet medical need for a product for the much larger market of treatment of general, non-infectious diarrhea in dogs,” said Lisa Conte, Jaguar’s Founder and CEO. “We estimate that U.S. veterinarians see approximately six million annual cases of acute and chronic diarrhea in dogs, and we look forward to identifying a partner to fund and execute development and commercialization of crofelemer for the treatment of general, non-infectious diarrhea in the U.S and/or globally. Forging a partnership for this purpose is a key focus of our business development efforts in 2025 and has been designated as a key potential catalyst for the company this year.”

“Jaguar’s canine-focused business development efforts align with our ongoing business development efforts on the ‘human’ side of the company for crofelemer – the catalysts for which are the pathways discussed with the FDA to bring crofelemer to metastatic breast cancer patients, a population we feel meets the requirements for orphan drug status; and the prompt establishment of an expanded access program for crofelemer for the ongoing important unmet medical need of cancer therapy-related diarrhea in breast cancer patients; and the initial proof-of-concept results from the ongoing investigator-initiated trial (IIT) of a novel liquid formulation of crofelemer in Abu Dhabi in pediatric patients with intestinal failure due to the orphan diseases microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF). As recently announced, the initial proof-of-concept results of this IIT show crofelemer reduced the required total parenteral nutrition (TPN) and/or supplementary intravenous fluids, collectively referred to as parenteral support, in patients with intestinal failure due to MVID and short bowel syndrome by up to 27% and 12.5% respectively.”

The objective of the prospective, randomized, open-label field study in dogs undergoing chemotherapy treatment across the U.S. is to collect real-world data to demonstrate real-world evidence of the clinical effectiveness for Canalevia-CA1 for the treatment of CID in dogs to support potential full FDA approval of the drug for this indication. Dogs enrolled in this study will be randomly assigned to receive a prescription of Canalevia-CA1 as a treatment for CID or be randomly selected to the control group.

As announced, Jaguar established a new Investigational New Animal Drug (INAD) file with the FDA’s Center for Veterinary Medicine for crofelemer to treat general, non-infectious diarrhea in dogs.

Diarrhea is one of the most common reasons for veterinary office visits for dogs and is the second most common reason for visits to the veterinary emergency room, yet there are currently no FDA-approved drug to treat canine general, non-infectious diarrhea. According to the American Veterinary Medical Association, there were an estimated 89.7 million dogs in the United States in 2024, with nearly half (45.5%) of U.S. households owning a dog in 2024. Devastating diarrhea-related dehydration can occur rapidly for the animal, and the lack of control in urban settings where owners don’t have easy access to outdoor facilities is a significant problem for families with dogs.

Canalevia-CA1, a canine-specific formulation of crofelemer, Jaguar’s novel, oral plant-based drug sustainably harvested from the Croton lechleri tree, is available from multiple leading veterinary distributors in the U.S., including Chewy.

About Conditional Approval and Full Approval

Canalevia-CA1 initially received conditional approval in December 2021 from the FDA for the treatment of CID in dogs. FDA’s conditional approval allows a drug company to legally promote, advertise and sell the animal drug for the labeled uses before proving it meets the “substantial evidence” standard of effectiveness for full approval. The conditional approval is valid for one year. The drug company can ask the FDA to renew the conditional approval annually for up to four more years, for a total of five years of conditional approval. To receive a renewal from the FDA, the company must show active progress toward proving “substantial evidence of effectiveness” for full approval. After collecting the remaining effectiveness data, the company then applies to the FDA for full approval. The FDA reviews the application and, if appropriate, fully approves the drug.

About Chemotherapy-induced Diarrhea (CID) in Dogs

According to the American Veterinary Medical Association, approximately 1 in 4 dogs will, at some stage in their life, develop cancer, and almost 50% of dogs over age 10 will develop cancer.¹ According to the National Cancer Institute, which is part of the National Institutes of Health, roughly 6 million new cancer diagnoses are made in dogs each year in the U.S.

Due to the increasing number of chemotherapeutic agents being adopted by veterinary oncologists and primary care veterinarians, chemotherapy is fast becoming the most widely used cancer treatment in veterinary medicine. Studies have found the incidence of CID to be one of the three most prevalent side effects in dogs undergoing cancer treatment,² and managing side-effects such as diarrhea can be important to maintain successful cancer treatment. More than half of the U.S. veterinarians who responded to a Jaguar-sponsored survey reported that CID interferes with their patients’ chemotherapy treatment plans, indicating an unmet need for an effective product for the treatment of CID.

Canalevia-CA1 is a tablet that can be given orally twice a day and can be used for home treatment of CID in dogs.

About Canalevia^®-CA1

Canalevia-CA1 (crofelemer delayed-release tablets) is the first and only oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea (CID) in dogs. Canalevia-CA1 is a canine-specific formulation of crofelemer, an active pharmaceutical ingredient isolated and purified from the Croton lechleri tree. Canalevia-CA1 is currently conditionally approved by the FDA under application number 141-552. Conditional approval allows for commercialization of the product while Jaguar continues to collect the substantial evidence of effectiveness required for full approval. Jaguar has also received Minor Use in a Major Species (MUMS) designation from the FDA for Canalevia-CA1 to treat CID in dogs. FDA has established a “small number” threshold for minor use in each of the seven major species covered by the MUMS act. The small number threshold is currently 80,000 for dogs, representing the largest number of dogs that can be affected by a disease or condition over the course of a year and still have the use qualify as a minor use.

About Crofelemer

Crofelemer is the only oral FDA-approved prescription drug under botanical guidance. It is plant-based, extracted and purified from the red bark sap of the Croton lechleri tree in the Amazon Rainforest. Napo Pharmaceuticals, a Jaguar family company, has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for Indigenous communities.

Important Safety Information About Canalevia^®-CA1

For oral use in dogs only. Not for use in humans. Keep Canalevia-CA1 (crofelemer delayed-release tablets) in a secure location out of reach of children and other animals. Consult a physician in case of accidental ingestion by humans. Do not use in dogs that have a known hypersensitivity to crofelemer. Prior to using Canalevia-CA1, rule out infectious etiologies of diarrhea. Canalevia-CA1 is a conditionally approved drug indicated for the treatment of chemotherapy-induced diarrhea in dogs. The most common adverse reactions included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting.

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. It is a violation of Federal law to use this product other than as directed in the labeling. Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar’s Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

For more information about:

Jaguar Health, visit https://jaguar.health

Napo Pharmaceuticals, visit www.napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Magdalena Biosciences, visit magdalenabiosciences.com

Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements.” These include statements regarding Jaguar’s expectation that it will identify a partner to fund and execute development and commercialization of crofelemer for the treatment of general, non-infectious diarrhea in dogs in the U.S and/or globally, Jaguar’s expectation that the U.S. population of metastatic breast cancer patients meets the requirements for orphan drug status, Jaguar’s expectation that it will promptly establish an expanded access program for crofelemer for cancer therapy-related diarrhea in breast cancer patients, and Jaguar’s expectation that the field study of Canalevia-CA1 for the treatment of CID in dogs will support potential full FDA approval of the drug for this indication. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

¹ “Cancer in Pets.” American Veterinary Medical Association, 2021, https://www.avma.org/resources/pet-owners/petcare/cancer-pets

² Mason SL, Grant IA, Elliott J, Cripps P, Blackwood L. Gastrointestinal toxicity after vincristine or cyclophosphamide administered with or without maropitant in dogs: a prospective randomised controlled study. J Small Anim Pract. 2014;55:391-398

Contact:

hello@jaguar.health

Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

View the original press release on ACCESS Newswire

Treatment reversed tremors, ataxia, anxiety-like behavior, liver and kidney pathology damage, reduced copper accumulation, normalized ALT, AST, and bilirubin levels, and improved survival.

Building on previous data in Werner syndrome, showing Telomir-1 reset the epigenetic clock, extended telomere length, restored gene expression, reversed muscle loss, and rescued survival-alongside data in Age Related Macular Degeneration (AMD) demonstrating retinal regeneration and restored vision-the drug continues to show broad regenerative potential across rare genetic degenerative diseases

MIAMI, FL / ACCESS Newswire / June 11, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the “Company,” a preclinical-stage biotechnology company focused on reversing biological aging and degenerative diseases, today announced compelling new preclinical data demonstrating that its lead drug candidate, Telomir-1, significantly reversed neurological, hepatic and kidney symptoms in a clinically relevant animal model of Wilson’s disease.

Wilson’s disease is a rare and potentially fatal genetic disorder caused by mutations in the ATP7B gene, which impair the body’s ability to eliminate excess copper. As copper builds up-primarily in the liver and brain-it leads to inflammation, tissue damage, and multi-organ dysfunction. Patients may experience liver failure, psychiatric disturbances, tremors, and progressive neurological decline. Current treatments involve lifelong copper chelation or liver transplantation, highlighting the urgent need for safer, disease-modifying therapies.

These new results build on earlier in vitro studies that confirmed Telomir-1’s high binding affinity for copper and its ability to exchange and regulate key ions. The current in vivo findings now confirm that Telomir-1’s copper-regulating properties translate into meaningful behavioral, physiological and histological improvements in a genetic animal model of Wilson’s disease.

In the ATP7B C271X -/- zebrafish model, which mimics human Wilson’s disease Telomir-1 demonstrated dose-dependent and statistically significant reversal of major disease features:

Key Findings from the Study:

• Up to a 4- to 5-fold reduction in episodic tremor events

• Normalization of swim distance, swim velocity, and exploratory behavior

• Reversal of ataxia-like motor behaviors (e.g., abnormal body bends and turn angles)

• Approximately 50% reduction in copper accumulation in dry liver tissue

• Marked improvement in liver and kidney histopathology, with liver and kidney scores reduced to near-normal levels

• Normalization of ALT, AST, and bilirubin-three critical liver biomarkers. ALT and AST are enzymes elevated during liver injury, while bilirubin builds up when detoxification is impaired. Telomir-1 restored these to wild-type levels, indicating protection of liver function and copper-induced damage

• Improved survival under high copper exposure conditions

“We’ve now seen Telomir-1 generate breakthrough results across some of the most challenging age-related and genetic diseases-including AMD, Wilson’s disease, cancer, progeroid and Werner syndromes, and early findings suggesting reversal of key factors in type 2 diabetes,” said Erez Aminov, Chairman and CEO of Telomir. “In our AMD model, Telomir-1 restored vision and regenerated retinal structure using FDA-recognized surrogate endpoints. In Werner syndrome, it reset the epigenetic clock and reversed hallmarks of accelerated aging. And in Wilson’s disease, we saw a reversal of neurological, liver and kidney damage. These results point to the broad therapeutic potential of Telomir-1 across diseases driven by cellular degeneration. We believe this positions Telomir-1 as a powerful new platform for longevity, neuroprotection, and regenerative medicine.”

“These recent findings establish Telomir-1 as a potent disease-modifying compound in a clinically relevant model of Wilson’s disease,” added Dr. Angel, Chief Scientific Advisor. “Its ability to reverse behavioral and neurological dysfunction, normalize histological and functional biomarkers, and extend survival underscores its therapeutic promise across both rare and age-related disorders.”

Telomir Pharmaceuticals is currently advancing Telomir-1 through IND-enabling studies and expects to file its first IND for a rare disease indication by year-end, with human clinical trials planned for the first half of 2026.

Cautionary Note Regarding Forward-Looking Statements

This press release, statements of Telomir’s management or advisors related thereto, and the statements contained in the news story linked in this release contain “forward-looking statements,” which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications, and the safety of Telomir-1.

Any forward-looking statements in this press release are based on Telomir’s current expectations, estimates and projections only as of the date of this release. These and other risks concerning Telomir’s programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which is on file with the SEC. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Contact Information

Helga Moya
info@telomirpharma.com
(786) 396-6723

SOURCE: Telomir Pharmaceuticals, Inc

View the original press release on ACCESS Newswire

New AI-powered platform turns conversations into insights for quality assurance, performance gains, and coaching opportunities – amplifying human decision-making without replacing it.

GAINESVILLE, FL / ACCESS Newswire / June 11, 2025 / Insight7, a leading developer of conversational intelligence solutions, today announced the official launch of its new Call Evaluation platform. Designed for everyday business users, the platform helps mid-market teams across sales, customer support, quality assurance (QA), customer experience, human resources (HR), and compliance analyze video and audio calls at scale to uncover business insights, score interactions, identify coaching opportunities, and drive faster, smarter decision-making. Whether the objective is performance evaluation, onboarding, QA, or compliance monitoring, Call Evaluation supports a wide range of use cases and adapts to the unique goals and workflows of each function.

Unlike legacy tools designed for massive contact centers or high-cost platforms focused on tech-sector sales teams, Call Evaluation is an easy-to-use, affordable, and template-driven solution built for frontline teams – no technical expertise required. It delivers value across departments by surfacing actionable conversation insights in ways that reflect how real teams work, not how tech stacks are structured.

“There’s a growing disconnect between what organizations actually need from AI and the autonomous agent hype dominating the conversation,” said Odun Odubanjo, CEO and former Shopify product leader. “Our customers don’t want black-box AI making decisions for them. They want tools that help them work smarter and faster. Our platform delivers exactly that – AI that amplifies human intelligence rather than attempting to replace it.”

The platform automatically transcribes, analyzes, and surfaces actionable insights, performance metrics, and coaching opportunities from conversations, helping teams evaluate reps, track improvement, and enhance customer experience in real-time. While many enterprise call center tools are built for Fortune 500s with large-scale budgets, Call Evaluation is designed for the mid-market, serving companies with 10-150 cross-functional team members who generate thousands of employee and customer calls each month and are ready to unlock greater visibility, consistency, and performance across their teams.

Key features of the Call Evaluation platform include:

• Call Performance Dashboards: Real-time visibility into caller/agent behavior, sentiment trends, keywords, and performance drivers.

• Custom Scorecards & Coaching Tools: Tailored evaluation criteria, rep-level coaching tips, and performance tracking.

• Starter Kits by Role & Industry: Out-of-the-box templates tailored for common business needs, designed to help teams across departments quickly activate call insights and adapt the platform to their unique workflows.

Early customers report significant efficiency gains in call quality assurance and rep development. Tri County Metals has used Insight7 to evaluate call performance across its customer support team. “Insight7 has been a game-changer in helping us evaluate our customer service reps with greater accuracy and efficiency,” said James Akins, Head of Organization and Staffing. “The team is incredibly responsive and detail-oriented. It’s unlike anything else we’ve seen in this space.”

Insight7’s Call Evaluation platform is now available. Teams looking to improve sales performance, customer experience, or QA that drives coaching and continuous improvement through smarter call analysis can learn more and request a demo at https://www.insight7.io. The launch coincides with Customer Contact Week in Las Vegas, the top event for CX leaders.

ABOUT INSIGHT7:

Insight7 is the developer of Call Evaluation, an AI-powered conversation intelligence platform built for mid-market teams. Designed to support a wide range of use cases, including quality assurance, performance evaluation, coaching, onboarding, and compliance, Insight7 helps organizations turn thousands of sales, support, and internal calls into actionable insights. Built for everyday business users, the platform empowers cross-functional teams to evaluate conversations at scale, drive continuous improvement, and make faster, smarter decisions. Founded by former Shopify product leader Odun Odubanjo, Insight7 is based in Gainesville, Florida, with a globally distributed team. Learn more at www.insight7.io.

MEDIA CONTACT:

Nina Pfister, MAG PR at E: nina@mooringadvisorygroup.com; P: 781-929-5620

# # #

SOURCE: Insight7

View the original press release on ACCESS Newswire

TORONTO, ON / ACCESS Newswire / June 11, 2025 / Consumer Choice Award (CCA) proudly announces Teachers on Call as the top provider in the tutoring category for the Toronto Central region. This marks the company’s ninth consecutive win, underscoring its continued excellence in personalized tutoring. In celebration, Teachers on Call has launched the VIP Teachers’ Lounge, a new Teacher Appreciation Program created to recognize and thank the educators who have been instrumental in the company’s success over the past 40 years. Supported by partners both big and small, this initiative highlights the invaluable contributions of teachers, school staff, and education leaders who go above and beyond for students every day. A proudly Canadian and family-operated business, Teachers on Call is also celebrating its 40th anniversary this year. This award is a testament to the company’s enduring leadership in education and its unwavering commitment to both empowering students and honouring professional educators.

^{Photography of the Teachers on Call team by Jennifer Allison from JSHUTTER Photography}

“We’re incredibly honoured to celebrate 40 years of tutoring service and our ninth consecutive Consumer Choice Award,” said Joanne Sallay, President & CEO of Teachers on Call. “This milestone belongs to the amazing community that surrounds us – families who value education, students and alumni achieving great things, and the certified teachers who are the heart and soul of what we do. We’re especially proud to have launched our VIP Teachers’ Lounge Appreciation Campaign this year, offering exclusive offers, giveaways, and updates to recognize and celebrate all educators, not just those on our tutoring team. Dedicated professional teachers have always set us apart, and we are so grateful for their lasting impact on generations of learners. Every student deserves the opportunity to reach their full academic potential with confidence, and we’re proud to be part of that journey.”

Since 1984, Teachers on Call has provided high-quality, one-on-one tutoring services to elementary and high school students from kindergarten to Grade 12. Their approach centres on pairing students with professional, provincially certified teachers who offer curriculum-based support in English, French, math, science, reading, numeracy, and more. In addition to subject-specific help, Teachers on Call also offers academic coaching in essential study skills, time management, and organization and planning strategies. With a personalized approach to learning, Teachers on Call ensures that students receive tailored academic support through both in-home and online tutoring options. The company’s mission is to empower students by equipping them with the skills and confidence needed to succeed in school, future careers, and life.

Teachers on Call understands that every student has unique learning needs. Their tutoring services are designed to support a wide range of academic goals – whether it’s reinforcing classroom learning, preparing for important exams, improving learning skills and work habits, or simply working toward a strong report card. From remediation to enrichment and everything in between, Teachers on Call offers tailored support to help students succeed at every stage. By working closely with families and schools, their certified teachers ensure that tutoring aligns with the student’s curriculum, making learning both effective and enjoyable.

The company’s tutors not only provide academic instruction but also serve as mentors, fostering a love of learning and encouraging students to develop critical thinking and problem-solving skills. Teachers on Call takes pride in its long-standing relationships with families and schools, offering consistent support as students grow and progress through their educational journey.

In an era where online education has become increasingly prevalent, Teachers on Call stands out as a Canadian leader in online tutoring. As an early adopter of this approach well before the pandemic, the company recognized the opportunity to provide a cost-effective and flexible solution that reaches more students while also creating high-paying jobs for certified teachers. Their online tutoring programs deliver the same personalized attention, engagement, and curriculum-based support as in-home sessions, all from the comfort and convenience of home. By combining innovation with a deep commitment to student success, Teachers on Call is helping to shape a more accessible and empowering future for education in Canada.

To learn more about Teachers on Call, CLICK HERE or visit www.teachersoncall.ca.

About Consumer Choice Award:
Consumer Choice Award has been recognizing and promoting business excellence in North America since 1987. Its rigorous selection process ensures that only the most outstanding service providers in each category earn this prestigious recognition. Visit www.ccaward.com to learn more.

Contact Information:
Sumi Saleh
Communications Manager
ssaleh@ccaward.com

SOURCE: Consumer Choice Award

View the original press release on ACCESS Newswire

WASHINGTON, DC / ACCESS Newswire / June 11, 2025 / AGS Health^® CEO Patrice Wolfe has been named to the Becker’s Hospital Review list of “Women in Health IT to Know” in 2025. The annual list recognizes women who are harnessing the power of health IT to help shape the future of the healthcare industry.

Wolfe has been at the helm of AGS Health, a leading provider of tech-enabled revenue cycle management (RCM) solutions and a strategic growth partner to healthcare providers across the U.S., for nearly six years. During her tenure, the company has evolved into a market leader in technology-led RCM solutions, strengthening its capabilities through strategic acquisitions and the organic development of proprietary technologies.

Central to Wolfe’s leadership is a bold vision for a frictionless revenue cycle powered by a hybrid intelligence model that seamlessly blends human expertise with the speed, scale, and precision of artificial intelligence (AI). This model enhances human decision-making with AI’s analytical power, creating a synergistic system designed to prioritize outcomes over narrowly defined metrics and point solutions.

“Healthcare leaders are seeking a more strategic approach to revenue cycle management-one that goes beyond transactional efficiency and focuses on delivering measurable financial and clinical outcomes,” said Wolfe. “That’s the philosophy behind our hybrid intelligence model. Our clients view us not merely as a vendor but as a long-term strategic partner. The success of our solutions is measured by the tangible impact we deliver, whether that’s increasing cash flow, reducing denials, or improving the patient financial experience.”

Under Wolfe’s leadership, AGS Health has introduced a series of transformative advancements aimed at modernizing and optimizing revenue cycle operations. Key innovations include the deployment of agentic automation, autonomous medical coding solutions, and hybrid intelligence solutions for front-end financial clearance and prior authorization processes. The company has also developed proprietary workflow orchestration tools that enhance the efficiency, accuracy, and decision-making capabilities of its service teams through intelligent automation and real-time data insights.

Wolfe also spearheaded the company’s geographic expansion into Mexico and the Philippines, broadening customers’ access to diverse, highly skilled talent pools that are uniquely suited for clinical administrative support roles.

In recognition of its strong workplace culture and employee engagement, AGS Health earned Great Place to Work^® certification in India, the United States, and the Philippines. The company also achieved significant industry recognition, including being named a Leader in Everest Group’s Medical Coding Operations PEAK Matrix^® Assessment and receiving four consecutive Leader and Star Performer designations in Everest Group’s RCM Operations evaluations.

Additional accolades under Wolfe’s tenure include being named “Most Improved Services Solution – Best in KLAS: Software & Services,” earning the KLAS Research and Censinet Cybersecurity Transparent designation, and receiving the UiPath AI25 Award along with the Data Security Council of India (DSCI) Excellence Award for Best Security Practices in an Organization.

“I am honored to be among such an elite group of women who are reshaping the healthcare industry,” says Wolfe. “But I did not achieve this honor alone; credit extends to the exceptional AGS Health team, which shares my commitment to leveraging the latest technologies to deliver exceptional quality to our healthcare customers.”

The women leaders recognized on Becker’s list, curated by the editorial team from nominations submitted across the healthcare ecosystem, utilize technology to drive meaningful change by streamlining administrative processes, enhancing care delivery, standardizing workflows, and elevating overall system efficiency. In its announcement, Becker’s Healthcare stated its pride in honoring trailblazing women in health IT for their unwavering commitment to improving healthcare, adding that their leadership and innovation are essential to the continued success of their organizations and the healthcare industry.

The complete list of Women in Health IT to Know can be accessed here.

About AGS Health

AGS Health is more than a revenue cycle management company-we’re a strategic partner for growth. Our distinctive methodology blends award-winning services with intelligent automation and high-touch customer support to deliver peak end-to-end revenue cycle performance and an empowering patient financial experience.

We employ a team of 15,000 highly trained and college-educated RCM experts who directly support more than 150 customers spanning a variety of care settings and specialties, including nearly 50% of the 20 most prominent U.S. hospitals and 40% of the nation’s 10 largest health systems. Our thoughtfully crafted RCM solutions deliver measurable revenue growth and retention, enabling customers to achieve the revenue to realize their vision.

# # #

Media Contact:

Liz Goar
NPC Creative Services
liz@npccs.com

SOURCE: AGS Health

View the original press release on ACCESS Newswire

NEW YORK, NY / ACCESS Newswire / June 11, 2025 / There are countless headlines about the “supply chain.” And most people just shrug, assuming it means their groceries might arrive late or that next-day delivery becomes two-day. But in its truest sense, “supply chain” goes much deeper – especially when it comes to its integrity. That concept is no longer just a logistical concern; it has become a core pillar of national security.

SMX (NASDAQ:SMX), a leader in converting physical items into secure digital records for circular economy applications, now finds itself at the center of this shift. And that’s no accident. Unlike any known tracking system, SMX’s technology is a critical ally for a defense sector under increasing scrutiny over foreign-sourced components and an urgent need for technological sovereignty.

More importantly, SMX’s technological arsenal is purpose-built for a moment when the Pentagon and its contractors are rethinking how they track, verify, and secure critical materials. SMX’s platform – featuring molecular-level tagging, blockchain authentication, and AI-driven lifecycle tracking – delivers more than innovation. It delivers certainty.

When the Front Line Begins at the Supply Chain

As highlighted in recent OAN reporting, that’s now an uncompromising benchmark. Because in the modern defense arena, vulnerability doesn’t start on the battlefield – it begins in the backend. Weapons systems, aircraft, cybersecurity hardware, and communication equipment are built with parts sourced from thousands of vendors. Any one of them could be a weak link. Counterfeit chips, tampered sensors, or unverified alloys don’t just represent quality concerns – they’re conduits for sabotage.

The good news? SMX shuts that vulnerability down at the source. Its molecular-level marking system embeds traceability directly into the material itself – long before it ever enters a warehouse, factory floor, or combat zone. More specifically, each component is invisibly tagged and tied to an unchangeable blockchain ledger that records every phase of its lifecycle: origin, movement, installation, and eventual disposal. Whether it’s a turbine blade, encrypted processor, or missile guidance chip, SMX makes it instantly verifiable – anywhere, anytime, with zero room for compromise.

There’s no ambiguity here. SMX technology checks every box, including policies centered on resilience, domestic sourcing, and end-to-end oversight. And that matters – because the need for tamper-proof tracking isn’t just a nice-to-have anymore. It’s quickly becoming a requirement.

Why SMX Technology Fits into the DoD’s New Playbook

And national security is just one dimension. SMX technology answers the call of multiple federal priorities: securing U.S. supply chains, preventing counterfeit parts, complying with ESG mandates, and ensuring that every component used in defense systems is documented, verifiable, and safe. It’s a streamlined solution to a growing list of problems.

SMX’s emergence as a strategic defense partner didn’t come from chasing headlines. It came from solving the kinds of problems that today’s national security infrastructure can no longer afford to overlook. The company has already demonstrated its value across industries like plastics, metals, and textiles – but its role in defense may be its most mission-critical application yet.

Yesterday’s OAN segment made the case clear: the future of defense readiness depends on more than firepower. It depends on knowing exactly where every bolt, circuit, and compound comes from- and ensuring it hasn’t been compromised. That’s the level of trust SMX brings to the table.

And in this context, trust isn’t optional. Because when it comes to national defense, “almost certain” isn’t good enough. Validation, authentication, and full accountability are non-negotiable. SMX delivers all of that – and more.

Sources and references

• https://www.oann.com/video/oan-contribution/u-s-adversaries-ramping-up-biohazard-cybersecurity-attacks/

About SMX (Security Matters) Public Limited Company
As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.

Forward-Looking Statements
The information in this press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “will,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this press release may include, for example: matters relating to the Company’s fight against abusive and possibly illegal trading tactics against the Company’s stock; successful launch and implementation of SMX’s joint projects with manufacturers and other supply chain participants of steel, rubber and other materials; changes in SMX’s strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; SMX’s ability to develop and launch new products and services, including its planned Plastic Cycle Token; SMX’s ability to successfully and efficiently integrate future expansion plans and opportunities; SMX’s ability to grow its business in a cost-effective manner; SMX’s product development timeline and estimated research and development costs; the implementation, market acceptance and success of SMX’s business model; developments and projections relating to SMX’s competitors and industry; and SMX’s approach and goals with respect to technology. These forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing views as of any subsequent date, and no obligation is undertaken to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. As a result of a number of known and unknown risks and uncertainties, actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include: the ability to maintain the listing of the Company’s shares on Nasdaq; changes in applicable laws or regulations; any lingering effects of the COVID-19 pandemic on SMX’s business; the ability to implement business plans, forecasts, and other expectations, and identify and realize additional opportunities; the risk of downturns and the possibility of rapid change in the highly competitive industry in which SMX operates; the risk that SMX and its current and future collaborators are unable to successfully develop and commercialize SMX’s products or services, or experience significant delays in doing so; the risk that the Company may never achieve or sustain profitability; the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the Company experiences difficulties in managing its growth and expanding operations; the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; the risk that SMX is unable to secure or protect its intellectual property; the possibility that SMX may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties described in SMX’s filings from time to time with the Securities and Exchange Commission.

Media contact:

ken@hawkpointmedia.com

SOURCE: SMX (Security Matters)

View the original press release on ACCESS Newswire

Beyond the Grid: Neutrino® Energy Group’s Strategy for Land, Sea, Sky, and Space

MUNICH, DE / ACCESS Newswire / June 11, 2025 / A global energy transition is no longer optional-it’s a necessity. But behind the scenes of solar and wind, another technology is entering industrial reality with far greater implications. Neutrinovoltaic technology, developed by the Neutrino® Energy Group, is not a distant concept. It’s an operational platform for decentralized, 24/7 energy generation that is now expanding into mobility, aerospace, marine systems, and even high-security communications.

Neutrinovoltaic technology converts the kinetic energy of neutrinos and other non-visible radiation into electricity. These omnipresent particles trigger atomic vibrations in a nanomaterial composed of alternating layers of graphene and doped silicon. The resulting resonant frequency is transformed into direct current. Far from ambient energy scavenging, this is a controlled, scalable generation method already powering advanced applications.

Power Without Fuel: The Neutrino Power Cube

The Neutrino Power Cube is a compact, modular, and emission-free energy system delivering 5 to 6 kilowatts of continuous power. Weighing just 50 kilograms, it operates silently and autonomously, independent of weather or location. With no fuel, no combustion, and no grid connection required, the Cube holds the potential to decentralize energy infrastructure and become a cornerstone of clean, off-grid power generation worldwide.

Autonomous Mobility: The Pi Car

The Pi Car applies neutrinovoltaic integration to electric vehicles. Instead of relying on traditional charging infrastructure, the Pi Car generates power continuously by embedding neutrinovoltaic materials into structural components like the body panels and roof. After an hour in ambient conditions, the vehicle can achieve up to 100 kilometers of additional range. Collaborators include Simplior Technologies for AI-based energy optimization, C-MET Pune for materials development, and SPEL Technologies for battery integration. The concept also supports retrofitting existing EV platforms to enhance range and energy independence.

Flight Beyond Limits: Pi Fly

Pi Fly is Neutrino® Energy Group’s aeronautics program, developing UAVs powered by onboard neutrinovoltaic systems and supercapacitor storage. Current prototypes include multirotor and flying wing models. The next phase targets autonomous VTOL aircraft for cargo delivery. Supporting this effort are mobile hydrogen refueling units, also powered by neutrinovoltaics, enabling off-grid aviation infrastructure.

Maritime Transformation: Nautic Pi

Nautic Pi brings this energy platform to the sea. Neutrinovoltaic-powered marine vessels are under conceptual development, allowing autonomous navigation without onboard fuel or external charging. The system is particularly suited for long-duration missions, remote operations, and submersible platforms.

Communication Breakthrough: Project 12742

Finally, Project 12742 explores neutrino-based data transmission. Unlike radio signals, neutrinos pass through dense materials with minimal interference. This allows for real-time, secure global communication even through rock, oceans, or planetary bodies-an enormous leap for high-security and interplanetary data systems.

As governments and industries seek viable decarbonization paths, the Neutrino® Energy Group is no longer just proposing solutions-it’s deploying them. With a multidisciplinary team of hundreds of researchers, engineers, and scientists from over 40 countries, strategic alliances, and a growing portfolio of high-impact applications, neutrinovoltaic technology isn’t coming-it’s already here. And it’s conquering the world.

Neutrino Energy Group
Neutrino Scientific Board
Holger Thorsten Schubart – CEO
Website: www.neutrino-energy.com

Related Video

https://www.youtube.com/watch?v=LiswrRR8H2Q

SOURCE: Neutrino Energy Group

View the original press release on ACCESS Newswire

NEW YORK, NY / ACCESS Newswire / June 11, 2025 / New to The Street (NTTS) and High Performance Battery Technology (HPB) announce the launch of the Future of Batteries (FOB) Summit, an exclusive gathering in New York City for industry leaders ready to scale solid-state battery production in the United States. This inaugural summit with the theme, ‘Bridging Innovation: From Proven European Battery Technology to Scalable US Manufacturing‘, will take place from June 17-19 in some of NYC’s most exclusive locations.

FOB Summit offers practical dialogue aimed at commercializing advanced solid-state battery technologies in the US market, crucial for renewable energy storage, electric mobility, and infrastructure resilience.

Vince Caruso, CEO of NTTS, said, “This summit brings European battery technology leaders into direct conversation with US manufacturers, investors and media. It’s all about real opportunities to license, produce and scale innovation here in the United States.”

“Bringing proven solid-state battery technology from Europe to US manufacturing is a pivotal step for sustainable energy security,” added Sebastian Heinz, CEO of HPB. “We are not here to discuss technology in theory. We are here to transfer it into manufacturing. Our battery technology is non-flammable, built for long life and more environmentally friendly than conventional batteries. The next step is execution in the American market and FOB is designed as a launchpad for these cross-Atlantic partnerships,” said Dr. Sebastian Heinz, CEO of HPB.

With confirmed speakers from Porsche Consulting, Jonas & Redmann, ZNL Energy, and McKinsey & Company, the summit convenes decision-makers for high-level conversations around licensing, infrastructure, and supply chain readiness.

Marcus Andreas Olsen, Business Development Manager at ZNL Energy, a separator technology provider said, “The US battery market requires a robust supply chain, safety, and consistent quality. At ZNL, we are contributing advanced separator technologies to make solid-state batteries more scalable. FOB brings together the kind of strategic dialogue and partnerships needed to make that possible.”

Dr. Ing. Harald Wanka from Jonas & Redmann, an automation and production systems company, will be joining the summit virtually from Germany. He added, “From automated production lines to technical execution, we know what is needed to scale. This summit is the right forum to align strategies and timelines.”

Taking place in iconic venues including the Blackbarn restaurant, FOB provides networking sessions to foster immediate and lasting business connections. With panels on licensing, policy alignment, and manufacturing scalability, attendees will explore solutions to real-world challenges facing battery commercialization.

US manufacturers and investors seeking to participate or learn more about the Future of Batteries Summit 2025 can apply via the event website: https://hpb.ch/fob-summit-2025-waitlist-0

Attendance is limited to ensure impactful interactions. If you would like to participate in the summit or have any questions for the organisers, write to Monica Brennan (Head of Communications) at NTTS: monica@newtothestreet.com.

About New to The Street (NTTS)

About Us – New to The Street

New to The Street is a premier multi-platform media brand and long-form TV series that features innovative public and private companies from around the globe. Broadcasting weekly as sponsored programming on Fox Business Network and Bloomberg Television, and digitally across a rapidly growing 2.5 million+ subscriber YouTube channel, New to The Street delivers powerful exposure to a national and international investor audience.

For over 15 years, our Emmy-nominated anchors and expert correspondents have conducted over 600 interviews from the floor of the New York Stock Exchange, Nasdaq MarketSite, and other iconic venues. We specialize in showcasing visionary leaders, cutting-edge technology, and disruptive ideas-providing companies with guaranteed television airtime, earned media distribution, and unparalleled social and outdoor billboard visibility.

Through our trademark segment Opportunities To Consider™, we offer viewers exclusive insight into the people, products, and strategies shaping the next generation of market success stories.

New to The Street is where founders become known, where innovation meets exposure, and where success leaves clues.

About High Performance Battery (HPB)

High Performance Battery Technology GmbH is a German company specializing in the research and development of a new generation of batteries with outstanding properties. The HPB Solid-State Battery is characterized by its non-flammability, extreme longevity and significantly improved environmental properties, and is already ready for series production thanks to an innovative production process. HPB cooperates with renowned European plant manufacturers for industrial production. High Performance Battery Technology GmbH, based in Bonn/DE, is a wholly owned subsidiary of High Performance Battery Holding AG, based in Teufen/CH, which is responsible for financing the research work.

Media Contact: Monica@NewtoTheStreet.com

SOURCE: New to The Street

View the original press release on ACCESS Newswire

Clear Start Tax Warns That Hitting $10,000 in IRS Debt Can Trigger Serious Consequences – Including Passport Restrictions and Federal Liens

IRVINE, CA / ACCESS Newswire / June 11, 2025 / If you owe the IRS less than $10,000, you might think you’re in the clear. But Clear Start Tax says crossing that five-figure threshold can quietly trigger a cascade of government actions – including federal tax liens, denied passport renewals, and enhanced IRS collection efforts.

Most taxpayers don’t realize that $10,000 is a critical line in the sand for several IRS enforcement triggers. In 2025, enforcement is faster and more automated than ever, meaning debts that creep over this threshold can lead to serious consequences before the taxpayer even receives a phone call.

“The number isn’t arbitrary,” says the Head of Client Solutions at Clear Start Tax. “Once your tax debt hits $10,000, multiple systems within the IRS and State Department can flag your account for escalating enforcement – and that includes federal lien filings and passport holds.”

What Happens at the $10,000 Mark

According to Clear Start Tax, several federal programs and IRS enforcement protocols use $10,000 as a key trigger point:

• Federal Tax Liens: Once debt crosses $10,000, the IRS may begin filing a public Notice of Federal Tax Lien, which attaches to property, credit, and assets.

• Passport Revocation: Under the FAST Act, the IRS can certify seriously delinquent tax debt over $59,000 (adjusted annually) to the State Department – but debts over $10,000 often trigger early scrutiny that can affect renewals or travel.

• FBAR Filing Requirement: U.S. persons with more than $10,000+ in foreign accounts at any point in the year must file an FBAR – Failure to do so can result in steep civil fines and even criminal charges.

• Levy Readiness: Debts over $10,000 often place taxpayers in line for wage garnishments or bank levies, especially if no resolution plan is in place.

“Crossing the $10,000 mark can quietly activate IRS systems that move fast and leave little room to react,” said the Head of Client Solutions at Clear Start Tax. “By the time a taxpayer realizes what’s happening, they may already be dealing with a lien, frozen accounts, or even passport issues.”

What You Can Do Before It Hits

Clear Start Tax emphasizes that the best strategy is to act before your balance reaches – or exceeds – the $10,000 threshold. Early intervention opens the door to more flexible IRS programs, such as:

• Installment Agreements: Monthly payments that prevent liens and enforcement

• Offer in Compromise: A negotiated settlement for less than you owe

• Lien Withdrawal Requests: Preventing or reversing lien filings

• Currently Not Collectible (CNC): A temporary freeze on collections for qualifying hardship cases

These options are often more accessible and more successful when applied proactively, before enforcement action has started.

How Clear Start Tax Helps

Clear Start Tax takes a preventive and personalized approach to tax debt relief, beginning with a full financial analysis to assess each client’s risk of enforcement. Their team communicates directly with the IRS to quickly halt any escalating actions and then builds a customized resolution plan tailored to the client’s income, assets, and financial hardship.

About Clear Start Tax

Clear Start Tax is a full-service tax liability resolution firm that serves taxpayers throughout the United States. The company specializes in assisting individuals and businesses with a wide range of IRS and state tax issues, including back taxes, wage garnishment relief, IRS appeals, and offers in compromise. Clear Start Tax helps taxpayers apply for the IRS Fresh Start Program, providing expert guidance in tax resolution. Fully accredited and A+ rated by the Better Business Bureau, the firm’s unique approach and commitment to long-term client success distinguish it as a leader in the tax resolution industry.

Need Help With Back Taxes?
Click the link below:
https://clearstarttax.com/qualifytoday/

Contact Information

Clear Start Tax
Corporate Communications Department
seo@clearstarttax.com
(949) 535-1627

SOURCE: Clear Start Tax

View the original press release on ACCESS Newswire